Russian Heart Failure Journal 2006year Pharmaco-economical analysis of levosimendane treatment in patients with severe, decompensated chronic heart failure
Pharmaco-economical analysis of levosimendane treatment in patients with severe, decompensated chronic heart failure
Belousov Yu.V., Belousov D.Yu., Grigorjev V.Yu., Beketov A.S., Popova N.Yu., Boyko E.A., Mednikov O.I.
Aim of study – Performing the pharmaco-economical analysis «cost/efficiency» of the levosimendane treatment in patients with decompensated, severe CHF, based on data from the study LIDO. Methodology. The CEA analysis: dobutamine vs. levosimendane. Results. Estimations showed that the mean cost of 6-month levosimendane treatment was higher than the dobutamine treatment. The cost of treatment per patient was 73,115 rub. ($2,565) and 8,985 rub. ($312) for levosimendane and dobutamine, respectively. The additional expenses were related with the higher price of levosimendane. The other expenses were similar in both groups. In the dobutamine group major expenses were related with hospitalization while in the levosimendane group – the cost of the drug itself. The levosimendane treatment increased the life expectancy with the annual 3% discounting of 0.35 years. In the Russian Federation, this provides an incremental (added) «cost/efficiency» ratio (ICER) of 183,228 rub. ($6,429) for each prevented event. Since the cost of hospitalization and concomitant therapy does not influence expenses, such ICER is due to the cost of levosimendane itself. Sensitivity analysis showed that the data obtained were reliable. Conclusion. Investments to levosimendane will increase the life-span of patients with decompensated CHF by 905 days and save from death additional 11 of 100 people. For the Russian Federation the use of levosimendane in patients with decompensated CHF is urgent because this drug possesses life-saving properties and is justified pharmaco-economically.